← Back to patent-cliff list
Risperidone Microspheres for Injection (Ⅱ)(Luye Pharma)
Tier C — Watch / tradeRisperidone Microspheres for Injection (Ⅱ)(Luye Pharma)
-
Originator
2021
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：5-HT2A, DRD2
Indications (approved)：Schizophrenia
Regional status
US
-
EU
-
China
Approved
2021-01-12
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Risperidone Microspheres for Injection (Ⅱ)(Luye Pharma)?
Approved indications include: Schizophrenia.
When does the Risperidone Microspheres for Injection (Ⅱ)(Luye Pharma) patent expire?
No public expiry year is available for Risperidone Microspheres for Injection (Ⅱ)(Luye Pharma) yet; this page updates once verified.
How do I get a quote for Risperidone Microspheres for Injection (Ⅱ)(Luye Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27